- Barr Labs announced Monday that it has amended its paragraph IV certification with respect to Lilly's Zyprexa Zydis patent to a paragraph III certification, and that Lilly has dropped its related patent suit against Barr. See also this AP article.
- FDA Law Blog had this post Tuesday about yet another new study on authorized generics.
- Patently-O reported today that the district court overseeing Abbott's Biaxin XL litigation against Sandoz has denied Sandoz's motion to stay a preliminary injunction pending appeal. For background, see this April OBB post.
- The Patent Prospector recently posted Hal Wegner's new paper on post-KSR chemical obviousness.
Editor
About
- The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.
Disclaimer
- Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.
Susbscribe
« Teva Defeats Novartis Motion for Preliminary Injunction in Lotrel Litigation | Main | Bristol-Myers Squibb and Sanofi-Aventis Prevail Over Apotex in Plavix Case »
June 16, 2007
The comments to this entry are closed.
Susbscribe
Search
Categories
- 180-Day Exclusivity (26)
- 271(e)(1) Safe Harbor (11)
- 271(e)(2) Jurisdiction (2)
- 30-Month Stay (3)
- Antitrust (49)
- Authorized Generics (20)
- Biosimilars (33)
- Citizen Petitions (22)
- Claim Construction (1)
- Claim Preclusion (1)
- Collateral Estoppel (2)
- Conferences (92)
- Declaratory Judgment Jurisdiction (25)
- FDA Announcements (7)
- FDA Litigation (12)
- Inequitable Conduct (4)
- Infringement--271(g) (1)
- Infringement--Direct (4)
- Infringement--Indirect (7)
- Inter Partes Review (6)
- Issue Preclusion (2)
- Orange Book Issues (27)
- Paragraph IV Cases (207)
- Patent Eligibility (2)
- Patent Term Extension (13)
- Pediatric Exclusivity (14)
- Pharma Business News (38)
- Preliminary Injunction (2)
- Prosecution (1)
- Section viii Statements (5)
- Validity--Novelty (6)
- Validity--Obviousness (22)
- Validity--Section 101 (2)
- Validity--Section 112 (6)
Comments